品牌分类
- 关注表位标记
- Primary Antibodies
- Recombinant Antibodies from Human Patients
- Anti-Allergen Antibodies
- 多标签控制蛋白
- Recombinant Isotype Controls
- 抗过敏原抗体
- 重组F4/80克隆CI:A3-1
- 体内研究用重组抗体
- Recombinant F4/80 Clone CI:A3-1
- Research-Grade Biosimilars
- 关注来自人类患者的重组抗体
- 同型对照
- 重组免疫球蛋白Fc结构域（Ig-Fc结构域）
- 人源性重组抗体
- 研究级生物仿制药
- 其他产品
- 抗病毒抗体
- 重组自由轻链
- Antibodies to Epitope Tags
- Anti-Virus Antibodies
品牌咨询
联系方式
公司地址
苏州工业园区生物纳米园A4#216
联系电话
4000-520-616 / 18915418616
传真号码
0512-67156496
电子邮箱
info@ebiomall.com
公司网址
https://www.ebiomall.com
蚂蚁淘在线 / 品牌中心 / Absolute Antibody / absoluteantibody/Ab00728-36.0 Anti-CD22 [hL22 (Epratuzumab)]/Ab00728-36.0/ 200 µg
商品描述
Description:RecombinantmonoclonalantibodytoCD22.ManufacturedusingAbAb’sRecombinantPlatformwithvariableregions(i.e.specificity)fromthehybridomahL22(Epratuzumab).
CloneNumber:hL22(Epratuzumab)
UniProtAccessionNumberofTargetProtein:P20273
PublishedApplication(s):Blocking;IP;FC
PublishedSpeciesReactivity:Human;RhesusMonkey;CynomolgusMonkey
Immunogen:ThisantibodywaspreparedbythehumanizationofLL2(EPB-2),amurineanti-CD22IgG2araisedagainstRajiBurkittlymphomacells.Murinesequencescomprise5–10%ofthemolecule,withtheremainderbeinghumanframeworksequences,whichgreatlyreducesthepotentialforimmunogenicity(Traczewski,2010).
Specificity:Thisantibodyisspecificforthe3rdIg-likedomainofhumanCD22(epitopeB),acellsurfaceglycoproteinpresentonmatureB-cellsandonmanytypesofmalignantB-cells.
ApplicationNotes:EpratuzumabbindstothethirdextracellulardomainofCD22,inducingCD22phosphorylation,resultinginnegativemodulationofBCRactivation,andrapidCD22internalization,leADIngtomodulationofB-cellhoming(Traczewski,2010).InitialphaseIIandtwoterminatedearlyphaseIIIstudiessuggestthattheuseofthisantibodytotreatsystemiclupuserythematosusiseffectiveandwelltolerated,butbothphaseIIItrialsfailedtomeetprimaryclinicalefficacyendpoints.Additionally,invitrostudiesandclinicaltrialsindicatethatthisantibodycanbeusedincombinationtherapywithanotherinhibitorofB-cellactivity,rituximab(anti-CD20),inthetreatmentofnon-Hodgkinlymphoma(Traczewski,2010).
AntibodyFirstPublishedin:
Pawlak-Byczkowskaetal.,Leungetal.Twonewmonoclonalantibodies,EPB-1andEPB-2,reactivewithhumanlymphoma&Constructionandcharacterizationofahumanized,internalizing,B-cell(CD22)-specific,leukemia/lymphomaantibody,LL2Cancerresearch,15August1989,Vol.49(16),pp.4568-77&MolecularImmunology,1995,Vol.32(17),pp.1413-1427Noteonpublication:Pawlak-Byczkowskaetal(1989)describestheuseofLL2(EPB-2)inIHCanalysistostainmalignantlymphomatissuesections.Leungetal(1995)describesthegenerationofahumanizedLL2antibody.
Concentration:Seeviallabel.
Importantnote–Thisproductisforresearchuseonly.Itisnotintendedforuseintherapeuticordiagnosticproceduresforhumansoranimals. Absolute Antibody我们现在与Digital Proteomics合作提供多克隆永生化服务。这意味着您可以生产可复制且不受限制的多克隆试剂，或者利用天然免疫系统来识别新的抗体候选物。对于这项服务，您可以提供免疫宿主生物的血清和B细胞，纯化的抗原用于免疫，或者只是告诉我们您的靶标，我们将做剩下的事情。鉴于其中之一，我们可以提供多达10条由发现引擎选择的重链序列和10条轻链序列，在交互式报告中提供具有蛋白质组学证据的扩展库，根据要求将抗体工程化为任何种类和同种型，以及我们提供的抗体表征数据获得。此服务是100％免版税的。 ThischimericcynomolgusmonkeyantibodywasmadeusingthevariabledomainsequencesoftheoriginalHumanIgG1format,forimprovedcompatibilitywithexistingreagents,assaysandtechniques.
SpeciesandIsotype:CynomolgusmonkeyIgG4,kappaCloneNumber:hL22(Epratuzumab)
UniProtAccessionNumberofTargetProtein:P20273
PublishedApplication(s):Blocking;IP;FC
PublishedSpeciesReactivity:Human;RhesusMonkey;CynomolgusMonkey
Immunogen:ThisantibodywaspreparedbythehumanizationofLL2(EPB-2),amurineanti-CD22IgG2araisedagainstRajiBurkittlymphomacells.Murinesequencescomprise5–10%ofthemolecule,withtheremainderbeinghumanframeworksequences,whichgreatlyreducesthepotentialforimmunogenicity(Traczewski,2010).
Specificity:Thisantibodyisspecificforthe3rdIg-likedomainofhumanCD22(epitopeB),acellsurfaceglycoproteinpresentonmatureB-cellsandonmanytypesofmalignantB-cells.
ApplicationNotes:EpratuzumabbindstothethirdextracellulardomainofCD22,inducingCD22phosphorylation,resultinginnegativemodulationofBCRactivation,andrapidCD22internalization,leADIngtomodulationofB-cellhoming(Traczewski,2010).InitialphaseIIandtwoterminatedearlyphaseIIIstudiessuggestthattheuseofthisantibodytotreatsystemiclupuserythematosusiseffectiveandwelltolerated,butbothphaseIIItrialsfailedtomeetprimaryclinicalefficacyendpoints.Additionally,invitrostudiesandclinicaltrialsindicatethatthisantibodycanbeusedincombinationtherapywithanotherinhibitorofB-cellactivity,rituximab(anti-CD20),inthetreatmentofnon-Hodgkinlymphoma(Traczewski,2010).
AntibodyFirstPublishedin:
Pawlak-Byczkowskaetal.,Leungetal.Twonewmonoclonalantibodies,EPB-1andEPB-2,reactivewithhumanlymphoma&Constructionandcharacterizationofahumanized,internalizing,B-cell(CD22)-specific,leukemia/lymphomaantibody,LL2Cancerresearch,15August1989,Vol.49(16),pp.4568-77&MolecularImmunology,1995,Vol.32(17),pp.1413-1427Noteonpublication:Pawlak-Byczkowskaetal(1989)describestheuseofLL2(EPB-2)inIHCanalysistostainmalignantlymphomatissuesections.Leungetal(1995)describesthegenerationofahumanizedLL2antibody.
ProductForm
Purification:ProteinAaffinitypurifiedSuppliedin:PBSonly.
StorageRecommendation:Storeat4°Cforupto3months.Forlongertermstoragealiquotintosmallvolumesandstoreat-20°CConcentration:Seeviallabel.
